FIELD: physics, pharmaceutics.
SUBSTANCE: invention relates to immunology, particularly to stable formulations of antibodies to the human programmed death receptor PD-1. Said formulations can be liquid or lyophilised, and contain 25-100 mg/ml antibody to human PD-1, about 70 mg/ml sucrose, about 0.2 mg/ml polysorbate 80 and about 10 mM histidine buffer at pH 5.0-6.0, where the antibody to human PD-1 is h409A11.
EFFECT: invention enables to obtain stable pharmaceutical formulations for treating patients with malignant growths or chronic viral infection.
7 cl, 18 dwg, 6 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| COMBINED THERAPY FOR MALIGNANT TUMOR TREATMENT | 2016 |
|
RU2733315C2 |
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| MULTIVALENT PD-L1-BINDING COMPOUNDS FOR TREATING MALIGNANT NEOPLASMS | 2020 |
|
RU2816646C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
